

Ref. No: 580100322
From: Commercial
Date: 10/03/22
Subject: Dermatological conditions

REQUEST

I am analysing the usage of new biologic medications for the treatment of dermatological conditions. I would greatly appreciate if you could answer the following question.

How many patients were treated in February 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Bimekizumab (Bimzelx)
- Brodalumab (Kyntheum)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)

RESPONSE

Pharmacy Response

Drug	Number of Patients treated in Feb 22 under Dermatology
Abrocitinib (Cibinqo)	0
Baricitinib (Olmiant)	0
Bimekizumab (Bimzelx)	0
Brodalumab (Kyntheum)	0
Dupilumab (Dupixent)	0
Ixekizumab (Taltz)	0
Risankizumab (Skyrizi)	<5
Guselkumab (Tremfya)	<5
Secukinumab (Cosentyx)	<5
Tildrakizumab (Ilumetri)	0
Tralokinumab (Adtralza)	0
Upadacitinib (Rinvoq)	0
Ustekinumab (Stelara)	7

Please note <5 : We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply.